atomoxetine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
serotonin and/or norepinephrine reuptake inhibitors, fluoxetine derivatives 256 83015-26-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • LY139603
  • strattera
  • atomoxetine
  • tomoxetine
  • (-)-Tomoxetine
  • atomoxetine hydrochloride
  • tomoxetine hydrochloride
  • atomoxetine HCl
  • tomoxetine HCl
A propylamine derivative and selective ADRENERGIC UPTAKE INHIBITOR that is used in the treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER.
  • Molecular weight: 255.36
  • Formula: C17H21NO
  • CLOGP: 3.94
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 1
  • TPSA: 21.26
  • ALOGS: -4.82
  • ROTB: 6

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
80 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 27.80 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 1.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 8.39 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 94 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.85 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 9.30 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.02 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 5.20 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Nov. 26, 2002 FDA LILLY

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Suicidal ideation 204.75 19.59 124 7752 56258 46621928
Prescribed overdose 175.13 19.59 66 7810 10383 46667803
Tic 114.38 19.59 29 7847 1207 46676979
Abnormal behaviour 99.40 19.59 55 7821 21003 46657183
Aggression 98.13 19.59 56 7820 22688 46655498
Irritability 83.23 19.59 55 7821 28891 46649295
Tachycardia 79.87 19.59 91 7785 99531 46578655
Crying 70.23 19.59 44 7832 21097 46657089
Suicide attempt 69.03 19.59 64 7812 54972 46623214
Agitation 68.65 19.59 64 7812 55351 46622835
Depression 62.91 19.59 107 7769 169997 46508189
Attention deficit hyperactivity disorder 60.39 19.59 20 7856 2152 46676034
Intentional self-injury 57.80 19.59 41 7835 24125 46654061
Disturbance in attention 52.24 19.59 43 7833 31517 46646669
Overdose 49.91 19.59 73 7803 101906 46576280
Raynaud's phenomenon 44.42 19.59 14 7862 1286 46676900
Myocarditis 44.32 19.59 23 7853 7716 46670470
Psychomotor hyperactivity 42.32 19.59 24 7852 9589 46668597
Mania 42.23 19.59 25 7851 10821 46667365
Somnolence 42.18 19.59 86 7790 156435 46521751
Intentional overdose 40.05 19.59 52 7824 64892 46613294
Electrocardiogram QT prolonged 39.57 19.59 46 7830 51279 46626907
Dystonia 38.81 19.59 24 7852 11233 46666953
Trichotillomania 38.74 19.59 8 7868 130 46678056
Impulsive behaviour 38.35 19.59 13 7863 1502 46676684
Anxiety 37.73 19.59 90 7786 181867 46496319
Anger 37.68 19.59 24 7852 11828 46666358
Supine hypertension 36.60 19.59 7 7869 75 46678111
Obsessive-compulsive disorder 35.35 19.59 15 7861 3200 46674986
Aspartate aminotransferase increased 35.14 19.59 54 7822 78646 46599540
Seizure 34.78 19.59 69 7807 122985 46555201
Loss of consciousness 34.66 19.59 64 7812 108174 46570012
Bipolar I disorder 34.22 19.59 12 7864 1534 46676652
Oppositional defiant disorder 33.91 19.59 6 7870 40 46678146
Educational problem 33.02 19.59 8 7868 275 46677911
Mydriasis 32.63 19.59 21 7855 10532 46667654
Heart rate increased 31.55 19.59 50 7826 74741 46603445
Mood swings 30.84 19.59 24 7852 16228 46661958
Renal tubular acidosis 30.18 19.59 11 7865 1572 46676614
Piloerection 28.32 19.59 7 7869 262 46677924
Thinking abnormal 26.62 19.59 18 7858 9796 46668390
Drug screen positive 26.48 19.59 13 7863 3878 46674308
Alanine aminotransferase increased 25.46 19.59 50 7826 88401 46589785
Liver injury 24.80 19.59 21 7855 15980 46662206
Dysmenorrhoea 24.62 19.59 12 7864 3526 46674660
Mood altered 24.23 19.59 19 7857 12988 46665198
Psychotic disorder 23.97 19.59 24 7852 22597 46655589
Social avoidant behaviour 23.96 19.59 11 7865 2828 46675358
Insomnia 23.46 19.59 71 7805 164853 46513333
Emotional disorder 22.95 19.59 18 7858 12306 46665880
Pneumonia 22.93 19.59 18 7858 376302 46301884
Feeling abnormal 22.86 19.59 59 7817 125001 46553185
Personality change 22.80 19.59 13 7863 5245 46672941
Merycism 21.63 19.59 5 7871 140 46678046
Rheumatoid arthritis 21.30 19.59 7 7869 240208 46437978
Generalised tonic-clonic seizure 20.38 19.59 24 7852 27098 46651088
Lymphocytic hypophysitis 20.36 19.59 5 7871 182 46678004
Diarrhoea 20.25 19.59 40 7836 559562 46118624

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Suicidal ideation 637.00 23.00 320 13896 35794 29902468
Tic 573.54 23.00 143 14073 1889 29936373
Aggression 549.76 23.00 292 13924 36615 29901647
Prescribed overdose 492.37 23.00 176 14040 8385 29929877
Abnormal behaviour 345.55 23.00 190 14026 25433 29912829
Anger 257.49 23.00 119 14097 11001 29927261
Irritability 233.55 23.00 142 14074 22908 29915354
Crying 201.95 23.00 82 14134 5527 29932735
Intentional self-injury 186.79 23.00 102 14114 13430 29924832
Testicular pain 170.64 23.00 60 14156 2712 29935550
Psychomotor hyperactivity 165.72 23.00 80 14136 8144 29930118
Oppositional defiant disorder 158.14 23.00 37 14179 365 29937897
Agitation 132.26 23.00 145 14071 53928 29884334
Homicidal ideation 127.86 23.00 47 14169 2416 29935846
Mood swings 126.48 23.00 65 14151 7561 29930701
Urinary hesitation 120.10 23.00 44 14172 2240 29936022
Disturbance in attention 118.39 23.00 92 14124 22037 29916225
Suicide attempt 116.04 23.00 113 14103 36584 29901678
Ejaculation disorder 116.04 23.00 35 14181 965 29937297
Impulsive behaviour 111.33 23.00 40 14176 1925 29936337
Attention deficit hyperactivity disorder 110.42 23.00 39 14177 1785 29936477
Acute kidney injury 109.23 23.00 5 14211 273837 29664425
Anxiety 104.13 23.00 167 14049 89704 29848558
Heart rate increased 101.93 23.00 108 14108 38613 29899649
Depressed mood 98.10 23.00 74 14142 16955 29921307
Death 97.45 23.00 25 14191 357258 29581004
Pneumonia 95.87 23.00 21 14195 334285 29603977
Mood altered 91.70 23.00 54 14162 8196 29930066
Depression 91.30 23.00 158 14058 90279 29847983
Hallucination, auditory 90.64 23.00 57 14159 9732 29928530
Bruxism 89.72 23.00 31 14185 1328 29936934
Somnolence 88.62 23.00 162 14054 96601 29841661
Decreased eye contact 85.63 23.00 23 14193 412 29937850
Insomnia 85.13 23.00 156 14060 93180 29845082
Drug screen positive 77.24 23.00 39 14177 4368 29933894
Mania 76.57 23.00 50 14166 9104 29929158
Palpitations 73.41 23.00 85 14131 33488 29904774
Psychotic disorder 73.17 23.00 69 14147 21446 29916816
Educational problem 72.98 23.00 19 14197 300 29937962
Dystonia 71.43 23.00 49 14167 9678 29928584
Mydriasis 70.35 23.00 41 14175 6102 29932160
Alanine aminotransferase increased 70.04 23.00 126 14090 74150 29864112
Product substitution issue 67.73 23.00 48 14168 9987 29928275
Self-injurious ideation 66.51 23.00 26 14190 1583 29936679
Tachycardia 64.36 23.00 121 14095 73618 29864644
Aspartate aminotransferase increased 62.88 23.00 110 14106 63312 29874950
Feeling abnormal 59.61 23.00 101 14115 56655 29881607
Electrocardiogram QT prolonged 59.47 23.00 79 14137 35756 29902506
Seizure 58.44 23.00 138 14078 98337 29839925
Anaemia 57.63 23.00 14 14202 207978 29730284
Sepsis 57.21 23.00 3 14213 146392 29791870
Dyskinesia 54.07 23.00 59 14157 21775 29916487
Diarrhoea 53.65 23.00 48 14168 334055 29604207
Penile discharge 53.34 23.00 11 14205 56 29938206
Retching 52.34 23.00 34 14182 6134 29932128
Blood alkaline phosphatase increased 51.60 23.00 69 14147 31418 29906844
Emotional disorder 50.53 23.00 31 14185 5063 29933199
Suicidal behaviour 49.30 23.00 20 14196 1342 29936920
Choreoathetosis 48.96 23.00 18 14198 925 29937337
Nervousness 48.31 23.00 42 14174 11746 29926516
Dysuria 45.82 23.00 55 14161 22486 29915776
Trismus 44.60 23.00 22 14194 2343 29935919
Generalised tonic-clonic seizure 43.55 23.00 50 14166 19501 29918761
Affect lability 42.30 23.00 24 14192 3394 29934868
Headache 40.93 23.00 183 14033 182123 29756139
Social avoidant behaviour 40.63 23.00 22 14194 2841 29935421
Gilbert's syndrome 40.37 23.00 8 14208 32 29938230
Growth retardation 39.75 23.00 18 14198 1582 29936680
Screaming 39.61 23.00 17 14199 1314 29936948
Obsessive-compulsive disorder 38.04 23.00 24 14192 4117 29934145
Enuresis 37.98 23.00 18 14198 1756 29936506
Blood bilirubin increased 36.86 23.00 64 14152 36572 29901690
Tearfulness 36.65 23.00 17 14199 1579 29936683
Sexual dysfunction 36.60 23.00 27 14189 5974 29932288
General physical health deterioration 36.22 23.00 3 14213 99941 29838321
Trichotillomania 36.14 23.00 8 14208 60 29938202
Paranoia 35.24 23.00 33 14183 10155 29928107
Renal failure 35.05 23.00 9 14207 128957 29809305
Thinking abnormal 34.90 23.00 25 14191 5286 29932976
Thrombocytopenia 34.60 23.00 11 14205 137033 29801229
Hepatic enzyme increased 34.34 23.00 59 14157 33435 29904827
Pallor 34.28 23.00 46 14170 21003 29917259
Negativism 34.12 23.00 11 14205 379 29937883
Coordination abnormal 33.98 23.00 28 14188 7277 29930985
Panic attack 33.70 23.00 30 14186 8651 29929611
Apathy 33.49 23.00 26 14190 6206 29932056
Personality change 33.36 23.00 23 14193 4577 29933685
Sleep disorder 31.76 23.00 48 14168 24431 29913831
Loss of consciousness 31.59 23.00 96 14120 79279 29858983
Physical assault 31.26 23.00 14 14202 1199 29937063
Abdominal pain upper 31.10 23.00 82 14134 62469 29875793
Fight in school 30.92 23.00 5 14211 3 29938259
Decreased appetite 30.30 23.00 146 14070 149764 29788498
Amphetamines positive 29.92 23.00 7 14209 69 29938193
Appendicitis 29.52 23.00 24 14192 6120 29932142
Respiratory failure 29.38 23.00 6 14210 100636 29837626
Cardiac failure 28.90 23.00 3 14213 83415 29854847
Tourette's disorder 28.82 23.00 7 14209 82 29938180
Repetitive speech 28.08 23.00 7 14209 92 29938170
Raynaud's phenomenon 27.78 23.00 9 14207 315 29937947
Syncope 27.74 23.00 96 14120 84807 29853455
Sedation 26.99 23.00 36 14180 16337 29921925
Hyperhidrosis 26.55 23.00 81 14135 67009 29871253
Abdominal discomfort 26.35 23.00 66 14150 48725 29889537
Pyrexia 25.98 23.00 64 14152 294425 29643837
Drug ineffective 25.62 23.00 260 13956 340127 29598135
Asthenia 25.61 23.00 41 14175 221249 29717013
Hostility 25.18 23.00 11 14205 888 29937374
Pyromania 25.04 23.00 6 14210 66 29938196
Hypotension 24.31 23.00 36 14180 200529 29737733
Oedema peripheral 24.15 23.00 10 14206 105822 29832440
Myocardial infarction 23.99 23.00 15 14201 125610 29812652
Dyspnoea 23.86 23.00 80 14136 333215 29605047
Dysphoria 23.70 23.00 14 14202 2134 29936128
Semen analysis abnormal 23.01 23.00 5 14211 34 29938228

Pharmacologic Action:

SourceCodeDescription
ATC N06BA09 NERVOUS SYSTEM
PSYCHOANALEPTICS
PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
Centrally acting sympathomimetics
FDA MoA N0000000102 Norepinephrine Uptake Inhibitors
FDA EPC N0000175695 Norepinephrine Reuptake Inhibitor
MeSH PA D018663 Adrenergic Agents
MeSH PA D018759 Adrenergic Uptake Inhibitors
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D014179 Neurotransmitter Uptake Inhibitors
CHEBI has role CHEBI:35469 thymoanaleptics
CHEBI has role CHEBI:35640 adrenergic uptake inhibitors
CHEBI has role CHEBI:35703 xenobiotic
CHEBI has role CHEBI:78298 environmental contaminants

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Attention deficit hyperactivity disorder indication 406506008
Delay when starting to pass urine contraindication 5972002
Priapism contraindication 6273006 DOID:9286
Suicidal thoughts contraindication 6471006
Sinus tachycardia contraindication 11092001
Bipolar disorder contraindication 13746004 DOID:3312
Hyperbilirubinemia contraindication 14783006 DOID:2741
Myocardial infarction contraindication 22298006 DOID:5844
Feeling agitated contraindication 24199005
Orthostatic hypotension contraindication 28651003
Hypertensive disorder contraindication 38341003 DOID:10763
Conduction disorder of the heart contraindication 44808001
Low blood pressure contraindication 45007003
Chronic heart failure contraindication 48447003
Feeling irritable contraindication 55929007
Aggressive behavior contraindication 61372001
Cerebrovascular disease contraindication 62914000 DOID:6713
Psychotic disorder contraindication 69322001
Cardiomyopathy contraindication 85898001 DOID:0050700
Structural disorder of heart contraindication 128599005
Seizure disorder contraindication 128613002
Liver function tests abnormal contraindication 166603001
Cerebrovascular accident contraindication 230690007
Mania contraindication 231494001
Disease of liver contraindication 235856003 DOID:409
Raynaud's phenomenon contraindication 266261006
Retention of urine contraindication 267064002
Pheochromocytoma contraindication 302835009
Angle-closure glaucoma contraindication 392291006 DOID:13550
Disorder of coronary artery contraindication 414024009
Myocardial infarction in recovery phase contraindication 418044006

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.32 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium-dependent noradrenaline transporter Transporter INHIBITOR Kd 8.69 CHEMBL CHEMBL
Sodium-dependent dopamine transporter Transporter Kd 5.97 CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 5.68 CHEMBL
Sodium-dependent serotonin transporter Transporter Kd 8.05 CHEMBL
Kir3.1/Kir3.2 Ion channel IC50 4.48 WOMBAT-PK
Kir3.1/Kir3.4 Ion channel IC50 4.84 WOMBAT-PK
G protein-activated inward rectifier potassium channel 2 Ion channel IC50 4.28 WOMBAT-PK
Cytochrome P450 2D6 Enzyme Ki 4.77 WOMBAT-PK
Krueppel-like factor 10 Unclassified IC50 4 CHEMBL
Sodium-dependent serotonin transporter Transporter Ki 7.37 CHEMBL
Transporter Transporter Ki 8.40 CHEMBL
Transporter Transporter Ki 9.15 CHEMBL
Sodium-dependent dopamine transporter Transporter Ki 5.85 CHEMBL

External reference:

IDSource
ASW034S0B8 UNII
D02574 KEGG_DRUG
82248-59-7 SECONDARY_CAS_RN
4021364 VANDF
4024296 VANDF
C0076823 UMLSCUI
CHEBI:127342 CHEBI
CHEMBL641 ChEMBL_ID
CHEMBL1702 ChEMBL_ID
54841 PUBCHEM_CID
DB00289 DRUGBANK_ID
D000069445 MESH_DESCRIPTOR_UI
5354 INN_ID
7118 IUPHAR_LIGAND_ID
353103 RXNORM
17042 MMSL
192105 MMSL
45567 MMSL
d04827 MMSL
009862 NDDF
009863 NDDF
407037005 SNOMEDCT_US
407038000 SNOMEDCT_US
412577007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Strattera HUMAN PRESCRIPTION DRUG LABEL 1 0002-3227 CAPSULE 10 mg ORAL NDA 37 sections
Strattera HUMAN PRESCRIPTION DRUG LABEL 1 0002-3228 CAPSULE 25 mg ORAL NDA 37 sections
Strattera HUMAN PRESCRIPTION DRUG LABEL 1 0002-3229 CAPSULE 40 mg ORAL NDA 37 sections
Strattera HUMAN PRESCRIPTION DRUG LABEL 1 0002-3238 CAPSULE 18 mg ORAL NDA 37 sections
Strattera HUMAN PRESCRIPTION DRUG LABEL 1 0002-3239 CAPSULE 60 mg ORAL NDA 37 sections
Strattera HUMAN PRESCRIPTION DRUG LABEL 1 0002-3250 CAPSULE 80 mg ORAL NDA 37 sections
Strattera HUMAN PRESCRIPTION DRUG LABEL 1 0002-3251 CAPSULE 100 mg ORAL NDA 37 sections
Atomoxetine HUMAN PRESCRIPTION DRUG LABEL 1 0093-3542 CAPSULE 10 mg ORAL ANDA 32 sections
Atomoxetine HUMAN PRESCRIPTION DRUG LABEL 1 0093-3543 CAPSULE 18 mg ORAL ANDA 32 sections
Atomoxetine HUMAN PRESCRIPTION DRUG LABEL 1 0093-3544 CAPSULE 25 mg ORAL ANDA 32 sections
Atomoxetine HUMAN PRESCRIPTION DRUG LABEL 1 0093-3545 CAPSULE 40 mg ORAL ANDA 32 sections
Atomoxetine HUMAN PRESCRIPTION DRUG LABEL 1 0093-3546 CAPSULE 60 mg ORAL ANDA 32 sections
Atomoxetine HUMAN PRESCRIPTION DRUG LABEL 1 0093-3547 CAPSULE 80 mg ORAL ANDA 32 sections
Atomoxetine HUMAN PRESCRIPTION DRUG LABEL 1 0093-3548 CAPSULE 100 mg ORAL ANDA 32 sections
Atomoxetine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2260 CAPSULE 10 mg ORAL ANDA 32 sections
Atomoxetine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2261 CAPSULE 18 mg ORAL ANDA 32 sections
Atomoxetine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2262 CAPSULE 25 mg ORAL ANDA 32 sections
Atomoxetine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2263 CAPSULE 40 mg ORAL ANDA 32 sections
Atomoxetine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2264 CAPSULE 60 mg ORAL ANDA 32 sections
Atomoxetine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2265 CAPSULE 80 mg ORAL ANDA 32 sections
Atomoxetine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2266 CAPSULE 100 mg ORAL ANDA 32 sections
Atomoxetine HUMAN PRESCRIPTION DRUG LABEL 1 0904-6908 CAPSULE 40 mg ORAL ANDA 31 sections
STRATTERA HUMAN PRESCRIPTION DRUG LABEL 1 16590-337 CAPSULE 10 mg ORAL NDA 35 sections
atomoxetine HUMAN PRESCRIPTION DRUG LABEL 1 16714-755 CAPSULE 10 mg ORAL ANDA 33 sections
atomoxetine HUMAN PRESCRIPTION DRUG LABEL 1 16714-756 CAPSULE 18 mg ORAL ANDA 33 sections
atomoxetine HUMAN PRESCRIPTION DRUG LABEL 1 16714-757 CAPSULE 25 mg ORAL ANDA 33 sections
atomoxetine HUMAN PRESCRIPTION DRUG LABEL 1 16714-758 CAPSULE 40 mg ORAL ANDA 33 sections
atomoxetine HUMAN PRESCRIPTION DRUG LABEL 1 16714-759 CAPSULE 60 mg ORAL ANDA 33 sections
atomoxetine HUMAN PRESCRIPTION DRUG LABEL 1 16714-760 CAPSULE 80 mg ORAL ANDA 33 sections
atomoxetine HUMAN PRESCRIPTION DRUG LABEL 1 16714-761 CAPSULE 100 mg ORAL ANDA 33 sections